Meta-Analysis of the Association between H63D and C282Y Polymorphisms in HFE and Cancer Risk

  • Zhang, Meng (Shenzhen Second People's Hospital, clinical medicine college of Anhui Medical University) ;
  • Xiong, Hu (The second Hospital of Lanzhou University) ;
  • Fang, Lu (The second affiliated hospital of Anhui Medical University) ;
  • Lu, Wei (Shenzhen Second People's Hospital, clinical medicine college of Anhui Medical University) ;
  • Wu, Xun (Department of Anatomy, School of Basic Medicine Science, Southern Medical University) ;
  • Wang, Yong-Qiang (Shenzhen Second People's Hospital, clinical medicine college of Anhui Medical University) ;
  • Cai, Zhi-Ming (Shenzhen Second People's Hospital, clinical medicine college of Anhui Medical University) ;
  • Wu, Song (Shenzhen Second People's Hospital, clinical medicine college of Anhui Medical University)
  • Published : 2015.06.26


Background: Previous studies suggested that the H63D and C282Y polymorphisms in the HFE genes were susceptible to many cancer types, nevertheless, the present results were inconclusive. Thus, the present study was aimed to evaluate the association between the HFE polymorphisms (H63D and C282Y) and cancer risk via meta-analysis. Materials and Methods: We retrieved PubMed, Google Scholar, Embase and Web of Science databases for all eligible studies up to April 1, 2015. All the statistical analysis was conducted by STATA 12.0. Results: Finally, a total of 20 publications including 24 case-control studies, comprising 6,524 cases and 31,080 controls for HFE-C282Y polymorphism and 19 publications including 21 case control studies, comprising 5,648 cases and 14,257 controls for HFE-H63D polymorphism were enrolled in our analysis. An increased risk for overall cancer risk was identified in HFE-H63D polymorphism under allele contrast (D vs H: OR=1.153; 95%CI=1.031-1.289, Pheterogeneity=0.002), homozygotes vs wide type (DD vs HH: OR=1.449; 95%CI=1.182-1.777, Pheterogeneity=0.391), dominant model (DD+HD vs HH: OR=1.145; 95%CI=1.007-1.301, Pheterogeneity=0.002) and recessive model (DD vs HD+HH: OR=1.416 ; 95%CI=1.156-1.735, Pheterogeneity=0.549), as well as HFE-C282Y under homozygotes vs wide type (YY vs CC: OR=1.428, 95%CI=1.017-2.006, Pheterogeneity=0.220). In addition, in the stratified analysis by cancer type, an increased risk was identified in hepatocellular carcinoma and breast cancer in C282Y polymorphism, as well as pancreatic cancer in H63D polymorphism, whereas a decreased risk of colorectal cancer was identified in C282Y polymorphism. Conclusions: Present study suggested that H63D and C282Y polymorphisms associated with an increased risk of overall cancer. Nevertheless, well-designed study with large sample size will be continued on this issue of interest.




Supported by : Natural Science Foundation of China


  1. Abraham BK, Justenhoven C, Pesch B, et al (2005). Investigation of genetic variants of genes of the hemochromatosis pathway and their role in breast cancer. Cancer Epidemiol Biomarkers Prev, 14, 1102-7.
  2. Adams PC, McLaren CE, Speechley M, et al (2013). HFE mutations in Caucasian participants of the Hemochromatosis and Iron Overload Screening study with serum ferritin level <1000 microg/L. Can J Gastroenterol, 27, 390-2.
  3. Agudo A, Bonet C, Sala N, et al (2013). Hemochromatosis (HFE) gene mutations and risk of gastric cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC) study. Carcinogenesis, 34, 1244-50.
  4. Batschauer AP, Cruz NG, Oliveira VC, et al (2011). HFE, MTHFR, and FGFR4 genes polymorphisms and breast cancer in Brazilian women. Mol Cell Biochem, 357, 247-53.
  5. Beckman LE, Van Landeghem GF, Sikstrom C, et al (1999). Interaction between haemochromatosis and transferrin receptor genes in different neoplastic disorders. Carcinogenesis, 20, 1231-3.
  6. Begg CB, Mazumdar M (1994). Operating characteristics of a rank correlation test for publication bias. Biometrics, 50, 1088-101.
  7. Boige V, Castera L, de Roux N, et al (2003). Lack of association between HFE gene mutations and hepatocellular carcinoma in patients with cirrhosis. Gut, 52, 1178-81.
  8. Cauza E, Peck-Radosavljevic M, Ulrich-Pur H, et al (2003). Mutations of the HFE gene in patients with hepatocellular carcinoma. Am J Gastroenterol, 98, 442-7.
  9. DerSimonian R, Laird N (1986). Meta-analysis in clinical trials. Control Clin Trials, 7, 177-88.
  10. Dubacq C, Chevalier A, Courbeyrette R, et al (2006). Role of the iron mobilization and oxidative stress regulons in the genomic response of yeast to hydroxyurea. Mol Genet Genomics, 275, 114-24.
  11. Egger M, Davey Smith G, Schneider M, et al (1997). Bias in meta-analysis detected by a simple, graphical test. BMJ, 315, 629-34.
  12. Ezzikouri S, El Feydi AE, El Kihal L, et al (2008). Prevalence of common HFE and SERPINA1 mutations in patients with hepatocellular carcinoma in a Moroccan population. Arch Med Res, 39, 236-41.
  13. Feder JN, Gnirke A, Thomas W, et al (1996). A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis. Nat Genet, 13, 399-408.
  14. Festa F, Kumar R, Sanyal S, et al (2005). Basal cell carcinoma and variants in genes coding for immune response, DNA repair, folate and iron metabolism. Mutat Res, 574, 105-11.
  15. Gharib AF, Karam RA, Pasha HF, et al (2011). Polymorphisms of hemochromatosis, and alpha-1 antitrypsin genes in Egyptian HCV patients with and without hepatocellular carcinoma. Gene, 489, 98-102.
  16. Graff RE, Cho E, Lindstrom S, et al (2014). Premenopausal plasma ferritin levels, HFE polymorphisms, and risk of breast cancer in the nurses' health study II. Cancer Epidemiol Biomarkers Prev, 23, 516-24.
  17. Gunel-Ozcan A, Alyilmaz-Bekmez S, Guler EN, et al (2006). HFE H63D mutation frequency shows an increase in Turkish women with breast cancer. BMC Cancer, 6, 37.
  18. Hucl T, Kylanpaa-Back ML, Witt H, et al (2007). HFE genotypes in patients with chronic pancreatitis and pancreatic adenocarcinoma. Genet Med, 9, 479-83.
  19. Kallianpur AR, Hall LD, Yadav M, et al (2005). The hemochromatosis C282Y allele: a risk factor for hepatic veno-occlusive disease after hematopoietic stem cell transplantation. Bone Marrow Transplant, 35, 1155-64.
  20. Kennedy AE, Kamdar KY, Lupo PJ, et al (2014). Examination of HFE associations with childhood leukemia risk and extension to other iron regulatory genes. Leuk Res, 38, 1055-60.
  21. Kondrashova TV, Neriishi K, Ban S, et al (2006). Frequency of hemochromatosis gene (HFE) mutations in Russian healthy women and patients with estrogen-dependent cancers. Biochim Biophys Acta, 1762, 59-65.
  22. Lauret E, Rodriguez M, Gonzalez S, et al (2002). HFE gene mutations in alcoholic and virus-related cirrhotic patients with hepatocellular carcinoma. Am J Gastroenterol, 97, 1016-21.
  23. Mantel N, Haenszel W (1959). Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst, 22, 719-48.
  24. Motawi TK, Shaker OG, Ismail MF, et al (2013). Genetic variants associated with the progression of hepatocellular carcinoma in hepatitis C Egyptian patients. Gene, 527, 516-20.
  25. Okada S (1996). Iron-induced tissue damage and cancer: the role of reactive oxygen species-free radicals. Pathol Int, 46, 311-32.
  26. Osborne NJ, Gurrin LC, Allen KJ, et al (2010). HFE C282Y homozygotes are at increased risk of breast and colorectal cancer. Hepatology, 51, 1311-8.
  27. Robinson JP, Johnson VL, Rogers PA, et al (2005). Evidence for an association between compound heterozygosity for germ line mutations in the hemochromatosis (HFE) gene and increased risk of colorectal cancer. Cancer Epidemiol Biomarkers Prev, 14, 1460-3.
  28. Rodriguez-Lopez R, Donoso M, Fernandez-Cavada M, et al (2013). Diagnostic utility of HFE variants in Spanish patients: association with HLA alleles and role in susceptibility to acute lymphoblastic leukemia. Gene, 514, 31-5.
  29. Ropero P, Briceno O, Lopez-Alonso G, et al (2007). [The H63D mutation in the HFE gene is related to the risk of hepatocellular carcinoma]. Rev Esp Enferm Dig, 99, 376-81.
  30. Shaheen NJ, Silverman LM, Keku T, et al (2003). Association between hemochromatosis (HFE) gene mutation carrier status and the risk of colon cancer. J Natl Cancer Inst, 95, 154-9.
  31. Shi Z, Johnstone D, Talseth-Palmer BA, et al (2009). Haemochromatosis HFE gene polymorphisms as potential modifiers of hereditary nonpolyposis colorectal cancer risk and onset age. Int J Cancer, 125, 78-83.
  32. Tobias A, Campbell MJ (1999). Modelling influenza epidemics in the relation between black smoke and total mortality. A sensitivity analysis. J Epidemiol Community Health, 53, 583-4.
  33. Torre LA, Bray F, Siegel RL, et al (2015). Global cancer statistics, 2012. CA Cancer J Clin, 65, 87-108.
  34. Weinberg ED (1996). The role of iron in cancer. Eur J Cancer Prev, 5, 19-36.
  35. Zamora-Ros R, Rothwell JA, Scalbert A, et al (2013). Dietary intakes and food sources of phenolic acids in the European Prospective Investigation into Cancer and Nutrition (EPIC) study. Br J Nutr, 110, 1500-11.
  36. Zhao Z, Li C, Hu M, et al (2014). Plasma ferritin levels, HFE polymorphisms, and risk of pancreatic cancer among Chinese Han population. Tumour Biol, 35, 7629-33.

Cited by

  1. Analysis of single nucleotide variants of HFE gene and association to survival in The Cancer Genome Atlas GBM data vol.12, pp.3, 2017,